Eaton Vance Management purchased a new stake in Cambrex Corp. (NYSE:CBM) during the second quarter, Holdings Channel reports. The fund purchased 6,540 shares of the company’s stock, valued at approximately $338,000.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Glenmede Trust Co. NA boosted its position in Cambrex Corp. by 15.7% in the first quarter. Glenmede Trust Co. NA now owns 11,888 shares of the company’s stock valued at $522,000 after buying an additional 1,612 shares during the period. Aperio Group LLC boosted its position in Cambrex Corp. by 3.0% in the first quarter. Aperio Group LLC now owns 7,576 shares of the company’s stock valued at $333,000 after buying an additional 221 shares during the period. Virginia Retirement System purchased a new position in Cambrex Corp. during the first quarter valued at $1,241,000. Ngam Advisors L.P. purchased a new position in Cambrex Corp. during the first quarter valued at $965,000. Finally, Teachers Advisors Inc. boosted its position in Cambrex Corp. by 3.9% in the first quarter. Teachers Advisors Inc. now owns 331,966 shares of the company’s stock valued at $14,607,000 after buying an additional 12,561 shares during the period. Institutional investors and hedge funds own 99.46% of the company’s stock.
Shares of Cambrex Corp. (NYSE:CBM) traded up 0.88% during mid-day trading on Friday, reaching $44.46. 582,725 shares of the company’s stock traded hands. Cambrex Corp. has a 12-month low of $29.50 and a 12-month high of $59.41. The stock has a market cap of $1.43 billion, a price-to-earnings ratio of 22.48 and a beta of 1.45. The firm’s 50 day moving average price is $45.06 and its 200-day moving average price is $47.67.
Cambrex Corp. (NYSE:CBM) last issued its quarterly earnings data on Thursday, July 28th. The company reported $0.68 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.59 by $0.09. Cambrex Corp. had a net margin of 13.97% and a return on equity of 24.86%. The business earned $118.22 million during the quarter, compared to analyst estimates of $114.85 million. During the same period in the prior year, the business earned $0.63 EPS. The company’s revenue for the quarter was up 10.9% on a year-over-year basis. Equities research analysts forecast that Cambrex Corp. will post $2.56 earnings per share for the current year.
Separately, Zacks Investment Research lowered shares of Cambrex Corp. from a “buy” rating to a “hold” rating in a research report on Wednesday, June 29th.
In related news, Director William B. Korb sold 3,420 shares of the stock in a transaction dated Monday, July 11th. The shares were sold at an average price of $55.00, for a total value of $188,100.00. Following the completion of the transaction, the director now directly owns 23,982 shares in the company, valued at approximately $1,319,010. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 2.63% of the stock is currently owned by corporate insiders.
Cambrex Corp. Company Profile
Cambrex Corporation (Cambrex) is a life sciences company. The Company provides products and services for the development and commercialization of new and generic therapeutics. The Company supplies its products and services across the world to generic pharmaceutical companies. Cambrex operates through three segments, which are manufacturing facilities.
Want to see what other hedge funds are holding CBM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cambrex Corp. (NYSE:CBM).
Receive News & Ratings for Cambrex Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex Corp. and related companies with MarketBeat.com's FREE daily email newsletter.